Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus
- PMID: 19035422
- PMCID: PMC2875149
- DOI: 10.1002/art.24063
Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus
Abstract
Objective: To estimate health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus (SLE) in the US.
Methods: Data were derived from the University of California, San Francisco Lupus Outcomes Study. Participants provided information on their health care resource use and employment. Cost estimates were derived for both direct health care costs and costs related to changes in work productivity. Direct health care costs included costs for hospitalizations, emergency department services, physician visits, outpatient surgical procedures, dialysis, and medications. Productivity costs were estimated by measuring changes in hours of work productivity since diagnosis of SLE; these estimates were also compared with normal US population data.
Results: For the total population of participants, the mean annual direct cost was $12,643 (2004 US dollars). The mean annual productivity cost for subjects of employment age (>or=18 and <65 years) was $8,659. The mean annual total cost (direct and productivity) for subjects of employment age was $20,924. Regression results showed that greater disease activity, longer disease duration, and worse physical and mental health were significant predictors of higher direct costs; older age predicted lower direct costs. Older age, greater disease activity, and worse physical and mental health status were significant predictors of higher costs due to changes in work productivity.
Conclusion: Both direct health care costs and costs associated with changes in work productivity are substantial and both represent important contributors to the total costs associated with SLE.
Figures
Similar articles
-
Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden.J Manag Care Spec Pharm. 2020 Mar;26(3):275-283. doi: 10.18553/jmcp.2020.26.3.275. J Manag Care Spec Pharm. 2020. PMID: 32105178 Free PMC article.
-
A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs.Arthritis Rheum. 1993 Nov;36(11):1548-59. doi: 10.1002/art.1780361109. Arthritis Rheum. 1993. PMID: 8240431
-
Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.Semin Arthritis Rheum. 2016 Jun;45(6):684-90. doi: 10.1016/j.semarthrit.2015.11.013. Epub 2015 Dec 2. Semin Arthritis Rheum. 2016. PMID: 26743074
-
Cost-of-illness studies in systemic lupus erythematosus: A systematic review.Arthritis Care Res (Hoboken). 2011 May;63(5):751-60. doi: 10.1002/acr.20410. Arthritis Care Res (Hoboken). 2011. PMID: 21557530 Review.
-
The economic burden of systemic lupus erythematosus.Best Pract Res Clin Rheumatol. 2012 Oct;26(5):695-704. doi: 10.1016/j.berh.2012.08.006. Best Pract Res Clin Rheumatol. 2012. PMID: 23218432 Review.
Cited by
-
Patient-reported outcomes and healthcare resource utilization in systemic lupus erythematosus: impact of disease activity.BMC Rheumatol. 2024 Jun 5;8(1):22. doi: 10.1186/s41927-023-00355-6. BMC Rheumatol. 2024. PMID: 38840229 Free PMC article.
-
Association of patient copayment and medication adherence in systemic lupus erythematosus.Lupus Sci Med. 2023 Oct;10(2):e000966. doi: 10.1136/lupus-2023-000966. Lupus Sci Med. 2023. PMID: 37852670 Free PMC article.
-
Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.Clinicoecon Outcomes Res. 2023 Jun 26;15:499-512. doi: 10.2147/CEOR.S410082. eCollection 2023. Clinicoecon Outcomes Res. 2023. PMID: 37397803 Free PMC article. Review.
-
Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry.Int J Environ Res Public Health. 2023 Feb 16;20(4):3522. doi: 10.3390/ijerph20043522. Int J Environ Res Public Health. 2023. PMID: 36834216 Free PMC article.
-
Cardiorespiratory Insufficiency and Performance Fatigability in Women with Systemic Lupus Erythematosus.Cardiopulm Phys Ther J. 2023 Jan;34(1):51-60. doi: 10.1097/cpt.0000000000000210. Epub 2022 Jul 13. Cardiopulm Phys Ther J. 2023. PMID: 36742346 Free PMC article.
References
-
- Yelin E, Callahan LF for the National Arthritis Data Work Group. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum. 1995;38:1351–1362. - PubMed
-
- Yelin E, Cisternas MG, Pasta DJ, Trupin L, Murphy L, Helmick CG. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum. 2004;50:2317–2326. - PubMed
-
- Yelin E, Herrndorf A1, Trupin L, Sonneborn D. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum. 2001;44:1160–1169. - PubMed
-
- Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health. 2000;3:243–252. - PubMed
-
- Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 2003;49:64–70. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
